Investment Insider: The heady days aren't over for drugs groups

Genetics, stem cells and consistent dividends can offset the problems of expiring patents

The further away an operation is from head office, the less control central management has over the operation. It is something, perhaps, that GlaxoSmithKline might be more mindful of in future.

However, the travails of the UK's biggest drugs company in China might provide investors with an opportunity to take a closer look at the group. The shares have enjoyed a decent run over the last two years, climbing from around 1,250p in 2011 to a recent high of 1,777p in May this year, and it is encouraging that they have only wavered a little following allegations of bribery against senior executives in the company's China office.

The bottom line is that GlaxoSmithKline is a generous dividend payer, and there is little to suggest this will stop in the near future. That might explain why the shares remain in demand. Profits this year are expected to rise around 3 per cent to almost £7bn, while the full-year dividend payout is expected to rise 7 per cent to 77p, which would suggest a dividend yield of 4.5 per cent based on the current share price of 1,715p.

AstraZeneca is now experiencing the same patent-expiry pains endured by GlaxoSmithKline in the last few years. Revenues fell around 20 per cent last year as key drugs lost their protection against generic rivals. That said, AstraZeneca is expected to keep shareholders sweet by at least maintaining its dividend. A forecast payout of 191p would equate to a yield of 5.8 per cent.

Much has been said about the pharmaceutical industry being in decline, and in a sense that's true as drugmakers cannot continue to dine out on the chemical drugs of yesteryear. However, as healthcare keeps evolving, so biologics and pharmaceuticals will gradually merge and the drug companies of the future will be involved in areas such as genetics, stem-cell science and a host of other medical technologies.

Among these companies, neither ReNeuron nor Xenetic Biosciences is currently profitable, but that is not unusual for fledgling firms at the cutting edge of science. ReNeuron, which is worth around £23m, specialises in developing stem-cell therapies in areas where medical needs have not been met. It has a treatment for stroke patients in clinical development.

Xenetic, which is worth around £26m, specialises in novel ways of delivering drugs and vaccines. It reckons that its pipeline has multi-billion-pound market potential.

The pharmaceutical sector is peppered with companies that believe they can be the next GlaxoSmithKline or Amgen. The trouble is, the risk-reward ratio when investing in small biotechnology firms can be quite high, given that only one in 15 drugs that enter clinical trials go on to make money. Conversely, the rewards can be huge for the drug that does make it through.

Investors, though, probably have as much chance of spotting the next GlaxoSmithKline as fledgling biotechs have of actually becoming one. If you want to improve your chances, investing a little in each company is one way to spread your risk.

Alternatively, stick to the big drug groups. Many have collaborated with the small biotechs, so they should at least have their finger on the pulse.

David Kuo is director of

Independent Partners; request a free guide on NISAs from Hargreaves Lansdown

Arts and Entertainment

Russell Brand at an anti-austerity march in June
peopleActor and comedian says 'there's no point doing it if you're not'
Arts and Entertainment
Banksy's 'The Girl with the Pierced Eardrum' in Bristol
art'Girl with the Pierced Eardrum' followed hoax reports artist had been arrested and unveiled
Oscar Pistorius is led out of court in Pretoria. Pistorius received a five-year prison sentence for culpable homicide by judge Thokozile Masipais for the killing of his girlfriend Reeva Steenkamp
voicesThokozile Masipa simply had no choice but to jail the athlete
Arts and Entertainment
Sister Cristina Scuccia sings 'Like a Virgin' in Venice

Like Madonna, Sister Cristina Scuccia's video is also set in Venice

Arts and Entertainment
James Blunt's debut album Back to Bedlam shot him to fame in 2004

Singer says the track was 'force-fed down people's throats'

Life and Style
The Tinder app has around 10 million users worldwide

techThe original free dating app will remain the same, developers say


Endangered species spotted in a creek in the Qinling mountains

peopleJust weeks after he created dress for Alamuddin-Clooney wedding
Life and Style
A street vendor in Mexico City sells Dorilocos, which are topped with carrot, jimaca, cucumber, peanuts, pork rinds, spices and hot sauce
food + drink

Trend which requires crisps, a fork and a strong stomach is sweeping Mexico's streets

Finacial products from our partners
Property search
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

ES Rentals

    iJobs Job Widget
    iJobs Money & Business

    Senior Pensions Administrator

    £23000 - £26000 Per Annum: Clearwater People Solutions Ltd: Our client is curr...

    Corporate Actions Administrator / Operations Administrator

    £25 - 30k: Guru Careers: A Corporate Actions Administrator / Operations Admini...

    Customer Service Executive / Inbound Customer Service Agent

    £18 - 23k + Benefits: Guru Careers: We are seeking a Customer Service Executiv...

    ASP.NET Web Developer / .NET Developer

    £60 - 65k + Benefits: Guru Careers: We are seeking a ASP.NET Web Developer / ....

    Day In a Page

    Two super-sized ships have cruised into British waters, but how big can these behemoths get?

    Super-sized ships: How big can they get?

    Two of the largest vessels in the world cruised into UK waters last week
    British doctors on brink of 'cure' for paralysis with spinal cord treatment

    British doctors on brink of cure for paralysis

    Sufferers can now be offered the possibility of cure thanks to a revolutionary implant of regenerative cells
    Let's talk about loss

    We need to talk about loss

    Secrecy and silence surround stillbirth
    Will there be an all-female mission to Mars?

    Will there be an all-female mission to Mars?

    Women may be better suited to space travel than men are
    Oscar Pistorius sentencing: The athlete's wealth and notoriety have provoked a long overdue debate on South African prisons

    'They poured water on, then electrified me...'

    If Oscar Pistorius is sent to jail, his experience will not be that of other inmates
    James Wharton: The former Guard now fighting discrimination against gay soldiers

    The former Guard now fighting discrimination against gay soldiers

    Life after the Army has brought new battles for the LGBT activist James Wharton
    Ebola in the US: Panic over the virus threatens to infect President Obama's midterms

    Panic over Ebola threatens to infect the midterms

    Just one person has died, yet November's elections may be affected by what Republicans call 'Obama's Katrina', says Rupert Cornwell
    Premier League coaches join the RSC to swap the tricks of their trades

    Darling, you were fabulous! But offside...

    Premier League coaches are joining the RSC to learn acting skills, and in turn they will teach its actors to play football. Nick Clark finds out why
    How to dress with authority: Kirsty Wark and Camila Batmanghelidjh discuss the changing role of fashion in women's workwear

    How to dress with authority

    Kirsty Wark and Camila Batmanghelidjh discuss the changing role of fashion in women's workwear
    New book on Joy Division's Ian Curtis sheds new light on the life of the late singer

    New book on Ian Curtis sheds fresh light on the life of the late singer

    'Joy Division were making art... Ian was for real' says author Jon Savage
    Sean Harris: A rare interview with British acting's secret weapon

    Sean Harris: A rare interview with British acting's secret weapon

    The Bafta-winner talks Hollywood, being branded a psycho, and how Barbra Streisand is his true inspiration
    Tim Minchin, interview: The musician, comedian and world's favourite ginger is on scorching form

    Tim Minchin interview

    For a no-holds-barred comedian who is scathing about woolly thinking and oppressive religiosity, he is surprisingly gentle in person
    Boris Johnson's boozing won't win the puritan vote

    Boris's boozing won't win the puritan vote

    Many of us Brits still disapprove of conspicuous consumption – it's the way we were raised, says DJ Taylor
    Ash frontman Tim Wheeler reveals how he came to terms with his father's dementia

    Tim Wheeler: Alzheimer's, memories and my dad

    Wheeler's dad suffered from Alzheimer's for three years. When he died, there was only one way the Ash frontman knew how to respond: with a heartfelt solo album